| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 38 |
| 1 | NIVOLUMAB | 37 |
| 2 | IPILIMUMAB | 28 |
| 3 | INFLIXIMAB | 14 |
| 4 | PREDNISONE | 13 |
| 5 | ADALIMUMAB | 11 |
| 6 | METHOTREXATE | 10 |
| 7 | METHOTREXATE SODIUM | 10 |
| 8 | PREDNISOLONE | 10 |
| 9 | PREDNISOLONE ORAL | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NATALIZUMAB-SZTN | 1 | 0.0042 |
| 1 | INTERLEUKIN-10 | 1 | 0.0028 |
| 2 | IPILIMUMAB | 28 | 0.0006 |
| 3 | INFLIXIMAB-DYYB | 2 | 0.0006 |
| 4 | AVELUMAB | 2 | 0.0005 |
| 5 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| 6 | SULINDAC | 1 | 0.0004 |
| 7 | PILOCARPINE HYDROCHLORIDE | 1 | 0.0004 |
| 8 | NIVOLUMAB | 37 | 0.0004 |
| 9 | PEMBROLIZUMAB | 38 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 28 | 0.0006 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 37 | 0.0004 |
| 2 | Amyloid Beta-directed Antibody [EPC] | 1 | 0.0003 |
| 3 | CD52-directed Cytolytic Antibody [EPC] | 5 | 0.0003 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 5 | Cannabinoid [EPC] | 1 | 0.0001 |
| 6 | Calcitonin Gene-related Peptide Antagonist [EPC] | 1 | 0.0001 |
| 7 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 8 | Potassium-sparing Diuretic [EPC] | 1 | 0.0001 |
| 9 | Nonergot Dopamine Agonist [EPC] | 1 | 0.0001 |